Abstract — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Co-founder & Chief Executive Officer)Scott Boyken(Co-founder & Chief Technology Officer)Stanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)Charity Scripture(Executive Officer)Eric Soller(Executive Officer)
XDof builds production-scale datasets, robotic systems, and tools for the robotics and physical AI industry.
AI & Machine LearningRoboticsBerkeley, US
Ding Jin(Executive Officer, Promoter)Shiyao Philipp Wu(Executive Officer, Director, Promoter)Yide Shentu(Executive Officer, Director, Promoter)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.